Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

In February 2026, Recursion Pharmaceuticals reported fourth-quarter 2025 revenue of US$35.54 million, sharply higher than a ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the AI stocks that will go to the moon. On February 18, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) came under pressure after regulatory ...

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...

The results of a recent survey released Tuesday showed President Trump's actions are likely to make it harder for biotech companies like Recursion to raise capital. The company reported ...

Recursion Pharmaceuticals (NASDAQ:RXRX) has experienced notable share price fluctuations in 2025, falling 27% year-to-date and trading over 55% beneath its 52-week high of $12. In spite of this ...

It’s got all the correct buzzwords for a hot biotech stock: machine learning, cell images, artificial intelligence. When Recursion Pharmaceutical went public at $18/share back in April, the stock ...